We have now found that 5-year survival was improved in primary melanoma cases with high PDCD4 expression, but no survival differences were seen when evaluating PDCD4 expression in metastatic disease using a TMA primarily consisting of extracranial metastases. This evidence concerns the gene PDCD4 and metastatic neoplasm.